GILEAD SCIENCES, INC. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax
GILEAD SCIENCES, INC. (GILD) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax of -$9.00 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax · last filed 2024-11-12
- GILEAD SCIENCES, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax for the quarter ending 2024-09-30 was -$9.00M, a 200.00% decline year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax for the quarter ending 2024-06-30 was $4.00M, a 300.00% increase year-over-year.
- GILEAD SCIENCES, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax for the quarter ending 2024-03-31 was $8.00M.
- GILEAD SCIENCES, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax for the quarter ending 2023-12-31 was -$11.00M.
- GILEAD SCIENCES, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax for fiscal 2023 was -$2.00M, a 110.00% decline from fiscal 2022.
- GILEAD SCIENCES, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax for fiscal 2022 was $20.00M, a 11.11% increase from fiscal 2021.
- GILEAD SCIENCES, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax for fiscal 2021 was $18.00M.
- GILEAD SCIENCES, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, tax for fiscal 2020 was -$15.00M.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$9.00M 10-Q · filed 2024-11-12 | -$5.00M derived: sum of 2 quarters · filed 2024-11-12 | $3.00M 10-Q · filed 2024-11-12 | -$8.00M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | $4.00M 10-Q · filed 2024-08-08 | $11.00M 10-Q · filed 2024-08-08 | $1.00M derived: sum of 3 quarters · filed 2024-08-08 | $10.00M derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-03-31 | $8.00M 10-Q · filed 2024-05-08 | -$3.00M derived: sum of 2 quarters · filed 2024-05-08 | $6.00M derived: sum of 3 quarters · filed 2024-11-12 | $7.00M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-12-31 | -$11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | -$2.00M derived: sum of 2 quarters · filed 2024-11-12 | -$1.00M derived: sum of 3 quarters · filed 2024-11-12 | -$2.00M 10-K · filed 2024-02-23 |
| 2023-09-30 | $9.00M 10-Q · filed 2024-11-12 | $10.00M derived: sum of 2 quarters · filed 2024-11-12 | $9.00M 10-Q · filed 2024-11-12 | -$8.00M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.00M 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | -$17.00M derived: sum of 3 quarters · filed 2024-08-08 | $4.00M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.00M 10-Q · filed 2024-05-08 | -$18.00M derived: sum of 2 quarters · filed 2024-05-08 | $3.00M derived: sum of 3 quarters · filed 2024-05-08 | $16.00M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $4.00M derived: sum of 2 quarters · filed 2024-02-23 | $17.00M derived: sum of 3 quarters · filed 2024-02-23 | $20.00M 10-K · filed 2024-02-23 |
| 2022-09-30 | $21.00M 10-Q · filed 2023-11-07 | $34.00M derived: sum of 2 quarters · filed 2023-11-07 | $37.00M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $13.00M 10-Q · filed 2023-08-04 | $16.00M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $3.00M 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | $18.00M 10-K · filed 2024-02-23 | |||
| 2020-12-31 | -$15.00M 10-K · filed 2023-02-22 | |||
| 2018-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $1.00M derived: sum of 2 quarters · filed 2019-02-26 | $2.00M derived: sum of 3 quarters · filed 2019-02-26 | $2.00M 10-K · filed 2019-02-26 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-06 | $1.00M derived: sum of 2 quarters · filed 2018-11-06 | $1.00M 10-Q · filed 2018-11-06 | $1.00M derived: sum of 4 quarters · filed 2019-02-26 |
| 2018-06-30 | $1.00M 10-Q · filed 2018-08-06 | $1.00M 10-Q · filed 2018-08-06 | $1.00M derived: sum of 3 quarters · filed 2019-02-26 | -$1.00M derived: sum of 4 quarters · filed 2019-02-26 |
| 2018-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2019-02-26 | $0.00 derived: sum of 2 quarters · filed 2019-02-26 | -$2.00M derived: sum of 3 quarters · filed 2019-02-26 | -$4.00M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$2.00M derived: sum of 2 quarters · filed 2019-02-26 | -$4.00M derived: sum of 3 quarters · filed 2019-02-26 | -$11.00M 10-K · filed 2019-02-26 |
| 2017-09-30 | -$2.00M 10-Q · filed 2018-11-06 | -$4.00M derived: sum of 2 quarters · filed 2018-11-06 | -$11.00M 10-Q · filed 2018-11-06 | |
| 2017-06-30 | -$2.00M 10-Q · filed 2018-08-06 | -$9.00M 10-Q · filed 2018-08-06 | ||
| 2016-12-31 | $0.00 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |